Emerging Company Profile: ImmuneOncia may be late entering the market for PD-L1 inhibitors, but the joint venture between Yuhan and Sorrento Therapeutics aims to develop best-in-class immuno-oncology drugs with differentiated products and strategy.
ImmuneOncia Therapeutics Inc. is a one-year-old immuno-oncology start-up that made a splash when it was established in South Korea by leading Korean pharma Yuhan Corp. and US-based biopharma Sorrento Therapeutics Inc.
It is the first R&D-based joint venture created by Yuhan – a milestone for the pharma, which strives to focus more on development of innovative novel drugs
“Yuhan has high expectations on ImmuneOncia
Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.
AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.
At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.
